Post-COVID syndrome, inflammation, and diabetes

The raging COVID-19 pandemic is in its third year of global impact. The SARS CoV 2 virus has a high rate of spread, protean manifestations, and a high morbidity and mortality in individuals with predisposing risk factors. The pathophysiologic mechanisms involve a heightened systemic inflammatory state, cardiometabolic derangements, and varying degrees of glucose intolerance. The latter can be evident as significant hyperglycemia leading to new -onset diabetes or worsening of preexisting disease. Unfortunately, the clinical course beyond the acute phase of the illness may persist in the form of a variety of symptoms that together form the so-called Long COVID or Post-COVID Syndrome. It is thought that a chronic, low-grade inflammatory and immunologic state persists during this phase, which may last for weeks or months. Although numerous insights have been gained into COVID-related hyperglycemia and diabetes, its prediction, course, and management remain to be fully elucidated.

Automated summary

The COVID-19 pandemic has been impacting the world for three years. The SARS CoV 2 virus spreads rapidly and has a high morbidity and mortality in individuals with risk factors. After the acute phase, patients may experience long-term symptoms known as Long COVID or Post-COVID Syndrome, which may be caused by chronic inflammation and immunologic state. The prediction, course, and management of COVID-related hyperglycemia and diabetes still need further elucidation.